



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

SPIL/CS/SE/2026-27/67

Date: 7th October 2026

The Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INE00TVO1023

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Updates on acquisition of M/s. Med Therapy Biotechnology Inc., USA – Company Letter bearing ref. no. SPIL/CS/SE/2026-2027/57 dated 5th September, 2026 and SPIL/CS/SE/2026-2027/58 dated 15th September, 2026

Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and in continuation of the Company's letters bearing ref. no. SPIL/CS/SE/2026-2027/57 dated 5th September, 2026 and SPIL/CS/SE/2026-2027/58 dated 15th September, 2026, this is to inform you that the proposal to acquire 9.50% equity shares of common stock of Med Therapy Biotechnology Inc., USA ("Med Therapy") stands terminated.

The proposal to acquire 1.50% each of the equity shares of common stock of Med Therapy, by Mr. Hemal Mehta (Chairman & Managing Director) and Mr. Sachin Mehta (Joint Managing Director), Promoters of the Company also stands terminated.

You are requested to take the same on record.

For, Sudarshan Pharma Industries Limited

HEMAL
VASANTRAJ
MEHTA
MEHTA

Digitally signed by
HEMAL VASANTRAJ
MEHTA
Date: 2026.10.07
12:36:09 +05'30'

Hemal Mehta
Chairman & Managing Director

